Omega-3 may help with depression that is already present if the product is rich in EPA, but it does not prevent depression in people who do not have it. A 2019 meta-analysis of 26 placebo-controlled trials found an overall beneficial effect, concentrated in formulations that were pure EPA or at least 60% EPA at 1 g a day or less, [liao-2019] while a 2021 trial of 18,353 adults found that 1 g a day of fish oil for a median of 5.3 years did not prevent depression. [okereke-2021] This guide covers what both studies found, what they could not show and what to ask a doctor. Our overview of depression covers the condition itself, and our guide to vitamin D for depression covers the other supplement tested in the same large trial.
Does omega-3 help depression?
As a treatment, possibly, if it is EPA-rich. As a way to prevent depression, no. The 2019 meta-analysis found that omega-3 polyunsaturated fatty acids had an overall beneficial effect on depression symptoms, and that the benefit came from EPA-rich formulations rather than DHA-rich ones. [liao-2019] The 2021 trial, which tested fish oil for prevention in adults without depression, found no benefit and a slightly higher risk of depression events in the omega-3 group. [okereke-2021]
The 2021 authors also put the treatment evidence in context: expert panels have supported omega-3 supplements for reducing recurrence of major depressive disorder in select high-risk patients but not broadly, and evidence for omega-3 as an add-on for major depressive disorder is modest and has not uniformly shown benefit. [okereke-2021]
What did the meta-analysis of 26 trials find?
It found a modest overall benefit, and a larger one for EPA. The 2019 team searched PubMed and EMBASE for double-blind, randomised, placebo-controlled trials published up to 20 December 2017. They found 180 articles and analysed 26 studies with 2,160 participants. Across all of them, omega-3 fatty acids showed an overall beneficial effect on depression symptoms (standardised mean difference 0.28 in favour of omega-3). [liao-2019]
The split by type mattered more. Compared with placebo, pure EPA and EPA-major formulations (60% EPA or more) showed clinical benefit at an EPA dose of 1 g a day or less (standardised mean differences of 0.50 and 1.03), whereas pure DHA and DHA-major formulations did not show such benefit. [liao-2019]
Effects versus placebo from the meta-analysis by Liao and colleagues (2019): 26 double-blind randomised trials, 2,160 participants. The paper reports these as negative values (-0.28, -0.50 and -1.03), where negative means fewer depression symptoms than placebo; they are shown here as positive sizes. The EPA figures are for an EPA dose of 1 g a day or less. DHA-pure and DHA-major formulations showed no such benefit, and the abstract gives no confidence intervals.
The authors concluded that current evidence supports omega-3 with at least 60% EPA at a dose of 1 g a day or less as beneficial for depression. They called for further studies in subgroups with inflammation, in different severities of depression, and on the dose response for both EPA and DHA. [liao-2019]
What did the five-year trial of 18,353 adults find?
It found that fish oil did not prevent depression. The VITAL-DEP trial, part of a larger US trial, randomised 18,353 adults aged 50 or over without depression or clinically relevant depressive symptoms to 1 g a day of fish oil (465 mg of EPA and 375 mg of DHA) or placebo, and followed them for a median of 5.3 years. [okereke-2021]
Depression or clinically relevant depressive symptoms occurred in 651 people on omega-3 (13.9 per 1,000 person-years) and 583 on placebo (12.3 per 1,000 person-years), a hazard ratio of 1.13 (95% confidence interval 1.01 to 1.26). Mood scores on the 8-item Patient Health Questionnaire did not differ: the mean difference in change was 0.03 points (95% confidence interval from 0.01 points better to 0.07 points worse on a scale where higher scores mean worse mood, a range that includes no difference). [okereke-2021]
An exploratory analysis found the higher risk limited to new depression in women (hazard ratio 1.38). The authors treated that as a signal for future work, not a finding, and concluded that the results do not support omega-3 supplements for preventing depression in adults. [okereke-2021]
Why does eating more fish look protective, if supplements are not?
Because observational studies and trials answer different questions. The 2021 authors noted that meta-analyses and large observational studies of dietary omega-3 and fish intake show protective associations, with relative risk reductions of 15% to 30% for higher versus lower intake. However, in analyses using gene variants to reduce bias and confounding, variants linked to plasma omega-3 concentration were not related to depression risk. [okereke-2021] An association between eating fish and lower depression risk does not show that a supplement will have the same effect.
| Question | What the studies found | Caveat |
|---|---|---|
| Helps existing depression? | Overall small benefit; larger for EPA-rich products (26 trials) | Abstract gives no confidence intervals |
| EPA or DHA? | EPA-rich helped; DHA-rich did not | Dose of 1 g a day or less |
| Prevents depression? | No: hazard ratio 1.13 over 5.3 years (18,353 adults) | Adults aged 50 or over without depression |
| Higher risk in women? | Hazard ratio 1.38 for new depression | Exploratory, not a finding |
| Side-effects? | Similar to placebo in the 2021 trial | One product, 1 g a day |
What can this research not show?
It cannot show whether omega-3 will help your depression, at what dose or alongside which treatment. Five limits matter most:
- The two studies ask different questions. One pooled trials in people with depression, and the other tested prevention in people without it, so they do not contradict each other. [liao-2019] [okereke-2021]
- The dose is unsettled. The 2019 analysis found benefit at 1 g a day or less, while a meta-regression in older adults cited by the 2021 authors suggested doses of 1.5 g a day or higher may be needed. [liao-2019] [okereke-2021]
- The 2019 abstract is thin on detail. It gives no confidence intervals for the EPA subgroups, so how firm each result is cannot be judged from it. [liao-2019]
- The big trial relied on self-report. Depression was assessed by questionnaire and self-reported diagnosis, few participants were likely to be severely deficient in omega-3, and suicidality was not measured. [okereke-2021]
- Neither covers children or younger adults. The 2021 trial enrolled adults aged 50 or over and says its results are not generalisable to children or younger adults. [okereke-2021]
What should you ask a doctor?
Ask whether an omega-3 supplement makes sense alongside any treatment you have, whether the product is EPA-rich, and what to do if it does not help. This section is our suggestion and is not something the studies tested. A supplement is not a replacement for treatment, and nothing here is a reason to stop a prescribed medicine.
Our guides to CBT for depression, new antidepressants and diet and depression cover other routes. If you want a rough picture of your mood before an appointment, our PHQ-9 depression screener is a short self-check. It is not a diagnosis, and it does not tell you whether omega-3 is right for you.
When to seek help
Speak to a doctor if low mood has lasted two weeks or more, if it is getting in the way of work, relationships or sleep, or if you are thinking about taking a supplement alongside treatment. If you have thoughts of harming yourself or feel unable to stay safe, contact your local emergency services or a crisis helpline.
How MyFreud can help
A record shows a doctor what has and has not helped. Daily mood tracking in MyFreud shows how your days run over weeks, and the notepad is somewhere to note what you took, how you slept and how your mood changed. It does not replace a doctor.
Download MyFreud and start today: App Store or Google Play.